ProShare Advisors
IMVT icon

ProShare Advisors’s Immunovant IMVT Stock Holding History

ProShare Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$690K Sell
17,904
-3,017
-14% -$91.9K ﹤0.01% 922
2026
Q1 		$520K Buy
20,921
+368
+2% +$9.53K ﹤0.01% 1040
2025
Q4 		$522K Buy
20,553
+2,660
+15% +$59.3K ﹤0.01% 1113
2025
Q3 		$288K Sell
17,893
-2,500
-12% -$40.5K ﹤0.01% 1455
2025
Q2 		$326K Buy
20,393
+165
+0.8% +$2.5K ﹤0.01% 1385
2025
Q1 		$346K Sell
20,228
-3,072
-13% -$64.3K ﹤0.01% 1319
2024
Q4 		$577K Buy
23,300
+3,681
+19% +$104K ﹤0.01% 1186
2024
Q3 		$559K Buy
19,619
+3,375
+21% +$99.5K ﹤0.01% 1075
2024
Q2 		$429K Sell
16,244
-3,633
-18% -$103K ﹤0.01% 1059
2024
Q1 		$642K Buy
19,877
+1,703
+9% +$62.1K ﹤0.01% 953
2023
Q4 		$766K Buy
18,174
+2,620
+17% +$96.4K ﹤0.01% 830
2023
Q3 		$597K Buy
15,554
+99
+0.6% +$2.24K ﹤0.01% 851
2023
Q2 		$293K Buy
15,455
+1,193
+8% +$22.2K ﹤0.01% 1287
2023
Q1 		$221K Sell
14,262
-2,147
-13% -$37.3K ﹤0.01% 1392
2022
Q4 		$291K Buy
16,409
+2,186
+15% +$27.5K ﹤0.01% 1252
2022
Q3 		$80K Buy
14,223
+659
+5% +$3.22K ﹤0.01% 1600
2022
Q2 		$53K Sell
13,564
-6,090
-31% -$26.3K ﹤0.01% 1696
2022
Q1 		$108K Sell
19,654
-5,301
-21% -$33K ﹤0.01% 2012
2021
Q4 		$212K Sell
24,955
-4,746
-16% -$39.2K ﹤0.01% 1991
2021
Q3 		$258K Buy
29,701
+2,366
+9% +$21.3K ﹤0.01% 1653
2021
Q2 		$289K Buy
27,335
+3,758
+16% +$52.5K ﹤0.01% 1921
2021
Q1 		$378K Buy
23,577
+162
+0.7% +$4.27K ﹤0.01% 1652
2020
Q4 		$1.08M Buy
+23,415
New +$1.08M ﹤0.01% 843

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ProShare Advisors's IMVT Position: Q2 2026 in Review

ProShare Advisors reduced its Immunovant (IMVT) stake by 14% in Q2 2026, selling an estimated $91.9K and leaving 17,904 shares worth $690K. The position accounts for ﹤0.01% of the portfolio, ranked #922.

ProShare Advisors first reported a position in IMVT in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.08M in Q4 2020. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • ProShare Advisors held 17,904 shares of Immunovant worth $690K as of Q2 2026.
  • ProShare Advisors sold 3,017 Immunovant shares in Q2 2026, an estimated $91.9K.
  • Immunovant made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #922 holding.
  • ProShare Advisors first reported a position in Immunovant in Q4 2020 and has held it in 23 quarters since.
  • ProShare Advisors's Immunovant position peaked at $1.08M in Q4 2020.
  • 227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.